Table 3.
Kaplan-Meier estimates for OS and TTF after the treatment with eribulin
| OS | TTF | |||||||
|---|---|---|---|---|---|---|---|---|
| Median, months | 1 year, % | 2 years, % | Median, months | 1 year, % | 2 years, % | |||
| n | (95% CI) | (95% CI) | (95% CI) | n | (95% CI) | (95% CI) | (95% CI) | |
| Alla) | 632 | 15.6 | 58.2 | 35.9 | 636 | 4.2 | 10.4 | 3.0 |
| (13.8–17.6) | (54.2–62.1) | (31.9–39.8) | (3.7–4.4) | (8.1–12.9) | (1.9–4.6) | |||
| First-line | 142 | 22.8 | 71.6 | 48.3 | 142 | 5.2 | 14.1 | 5.6 |
| (17.3–31.0) | (63.2–78.4) | (39.6–56.6) | (3.7–5.9) | (9.0–20.3) | (2.6–10.3) | |||
| Second-line | 175 | 16.3 | 58.2 | 37.0 | 177 | 4.2 | 11.9 | 2.8 |
| (12.4–19.9) | (50.3–65.2) | (29.5–44.6) | (3.7–5.1) | (7.6–17.1) | (1.1–6.1) | |||
| Third or later-line | 314 | 12.6 | 52.0 | 29.5 | 316 | 3.8 | 7.9 | 2.0 |
| (11.2–15.1) | (46.1–57.5) | (24.2–34.9) | (3.5–4.2) | (5.3–11.2) | (0.8–4.0) | |||
CI confidence interval
a)One patient whose number of previous chemotherapy regimens was unknown was included in the analysis. Overall survival (OS) was defined as the time from the first eribulin dose administration until all-cause death. Time to treatment failure (TTF) was defined as the time from the first eribulin dose administration until the date of treatment discontinuation from any cause